Search research articles
Contact Us
Filters
Showing results (121-130 of 161) with videos related to
Page
of 17
Sort By:
BMC Cancer
|
October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study
Christelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
Annals of Surgery
|
August 13, 2019
Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial
Christophe Mariette, Sheraz Markar, Tienhan Sandrine Dabakuyo-Yonli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2015
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients
Frédéric Fiteni, Dewi Vernerey, Franck Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2016
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
Gérard Lledo, Florence Huguet, Benoist Chibaudel, et al.
The New England Journal of Medicine
|
January 10, 2019
Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
Christophe Mariette, Sheraz R Markar, Tienhan S Dabakuyo-Yonli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
Olivier Bouché, Jean Luc Raoul, Franck Bonnetain, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology
Momar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)
Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
The Oncologist
|
March 22, 2015
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Xavier Pivot, Laura Mansi, Loic Chaigneau, et al.
Journal of the National Cancer Institute
|
April 7, 2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Angélique Vienot, Guillaume Beinse, Christophe Louvet, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 161) with videos related to
Sort By:
Page
of 17
BMC Cancer
|
October 27, 2016
Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study
Christelle d'Engremont, Dewi Vernerey, Anne-Laure Pointet, et al.
Annals of Surgery
|
August 13, 2019
Health-related Quality of Life Following Hybrid Minimally Invasive Versus Open Esophagectomy for Patients With Esophageal Cancer, Analysis of a Multicenter, Open-label, Randomized Phase III Controlled Trial: The MIRO Trial
Christophe Mariette, Sheraz Markar, Tienhan Sandrine Dabakuyo-Yonli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 20, 2015
Prognostic value of health-related quality of life for overall survival in elderly non-small-cell lung cancer patients
Frédéric Fiteni, Dewi Vernerey, Franck Bonnetain, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2016
Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX
Gérard Lledo, Florence Huguet, Benoist Chibaudel, et al.
The New England Journal of Medicine
|
January 10, 2019
Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer
Christophe Mariette, Sheraz R Markar, Tienhan S Dabakuyo-Yonli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 30, 2004
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803
Olivier Bouché, Jean Luc Raoul, Franck Bonnetain, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
November 30, 2015
Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology
Momar Diouf, Thomas Filleron, Anne-Laure Pointet, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 3, 2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM)
Isabelle Trouilloud, Anne-Claire Dupont-Gossard, David Malka, et al.
The Oncologist
|
March 22, 2015
In the era of genomics, should tumor size be reconsidered as a criterion for neoadjuvant chemotherapy?
Xavier Pivot, Laura Mansi, Loic Chaigneau, et al.
Journal of the National Cancer Institute
|
April 7, 2017
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Angélique Vienot, Guillaume Beinse, Christophe Louvet, et al.
Page
of 17